Henriksen J M, Dahl R
Am Rev Respir Dis. 1983 Dec;128(6):993-7. doi: 10.1164/arrd.1983.128.6.993.
The effect of aerosolized terbutaline in a dose of 32.5 micrograms and its placebo, administered in a double-blind fashion, was studied in 14 children with exercise-induced asthma (EIA) before and during a 4-wk treatment period with aerosolized steroid (budesonide, 400 micrograms/day). Effects were assessed from the changes in peak expiratory flow (PEF), forced expiratory volume in one second (FEV1), and forced expiratory flow (FEF25-75) before and after treadmill exercise challenge. Compared with placebo there was a significant improvement in pulmonary function after terbutaline. During budesonide therapy, pulmonary function improved further, but there was no enhancement of the response to terbutaline. Terbutaline alone, budesonide plus placebo, and budesonide plus terbutaline reduced the exercise-induced fall in FEV1 by 30, 51, and 84%, respectively. The effect of budesonide on EIA was delayed during the 4 wk of treatment as compared with the improvement in resting pulmonary function. The present results suggest that 1 to 4 wk of therapy with inhaled corticosteroids decreases the severity of EIA. Further, the combined effect of inhaled corticosteroid and beta-2 agonist on pulmonary function appears to be additive.
以双盲方式给14名运动诱发性哮喘(EIA)患儿分别给予剂量为32.5微克的雾化特布他林及其安慰剂,并在为期4周的雾化类固醇(布地奈德,400微克/天)治疗期之前和期间进行研究。通过跑步机运动激发前后的呼气峰值流速(PEF)、一秒用力呼气量(FEV1)和用力呼气流量(FEF25-75)变化来评估效果。与安慰剂相比,特布他林治疗后肺功能有显著改善。在布地奈德治疗期间,肺功能进一步改善,但对特布他林的反应未增强。单独使用特布他林、布地奈德加安慰剂以及布地奈德加特布他林分别使运动诱发的FEV1下降减少了30%、51%和84%。与静息肺功能的改善相比,布地奈德对EIA的作用在4周治疗期间有所延迟。目前的结果表明,吸入性皮质类固醇治疗1至4周可降低EIA的严重程度。此外,吸入性皮质类固醇和β-2激动剂对肺功能的联合作用似乎具有相加性。